Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

BCOP > BMT > Flashcards

BMT Flashcards

(73 cards)

Start Studying
1
Q

Rationale for HSCT -auto

A

 Dose intensify chemotherapy

 Stem cell rescue from myeloablative chemotherapy

 Non-hematopoietic organ toxicity becomes dose-limiting

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Rationale for HSCT -allo

A

 Stem cell rescue from myeloablative chemotherapy

 Establish a graft-versus- malignancy effect to destroy recipient cancer cells

 Replace missing or abnormal hematopoietic component

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Types of Transplant - anatomical source

A

 Bone marrow (BMT)

 Peripheral blood (PBSCT)

 Umbilical cord blood (UCB

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Types of Transplant - immunologic source

A 
 Allogeneic
   Matched related donor (MRD)
   Mismatched related donor (MMRD) or haploidentical
   Matched unrelated donor (MUD)
   Mismatched unrelated donor (MMUD)

 Syngeneic

 Autologous

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Selection of HSC Source - Recipient Factors -4

A

 Type and stage of recipient disease

 Donor availability

 Age

 Performance status

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Selection of HSC Source - Donor Factors -7

A

 HLA match

 Age

 Sex

 Number pregnancies in female donor

 Blood type and ABO compatibility

 Serologic status for cytomegalovirus

 Matched race

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

HLA Matching -serology vs DNA

A

S: Identifies HLA molecules on the cell surface using antigen specific anti-sera

D: Identifies HLA molecules by defining the DNA code in the cell nucleus

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

slide 5C

A

&&&

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Umbilical Cord Blood Stem Cells - Advantages -5

A

 Ease of procurement & faster availability than MUD

 Lower immunogenicity in cord blood leading to lower rates of severe GVHD (permitting 1-2 antigen-mismatch)

 Advantage of a lower transmission rate of infectious and genetic diseases

 Increased units for ethnic minorities and patients with rare haplotypes

 Frozen in small volumes; DMSO content is minimized

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Umbilical Cord Blood Stem Cells - Disdvantages -5

A

 Low number of stem cells in cord units

 Cost

 Lack of donor lymphocyte infusions

 Lack of experience and long-term
outcomes

 High rate of acquired infection

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

slide 6B

A

&&&

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

most common source of marrow

A

kids: BM
adults: peri blood

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Adult Acute Lymphoblastic Leukemia (ALL) Timing of Transplant Consultation -3

OS early tx 40%

what are high risk feautures -5

A

 CR1 up to age 35 for standard risk

 CR1 over age 35 if high risk
 Poor-risk cytogenetics (e.g., (t(9;22 or 11q23))
 High WBC (>30-50 x 109/L) at diagnosis
 CNS or testicular leukemia
 No CR within 4 weeks of initial treatment
 Induction failure

 CR2 and beyond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adult ALL Key Recommendations -5

A

 Allogeneic HSCT is recommended in CR1 for all risk groups based on a survival benefit &&&

 Autologous HSCT is an alternative if there is no allogeneic donor (similar survival to maintenance chemo with shorter treatment duration)

 Imatinib therapy before and after allogeneic HSCT should be considered

 TBI based conditioning may be preferred

 RIC only if they unsuitable for myeloablative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Adult Acute Myeloid Leukemia (AML) Timing of Transplant Consultation -3

OS early 50%

AML high risk feautures -3

A

 High-risk AML including
 Antecedent hematological disease (e.g., myelodysplastic syndromes)
 Treatment-related leukemia
 Induction failure

 CR1 with poor-risk cytogenetics or molecular
markers

 CR2 and beyond

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Adult AML Key Recommendations -3

what about low risk cytogenetics? -1

intermediate risk? -1

A

 Allogeneic HCST in CR1 confers a survival benefit over conventional chemotherapy in high-risk cytogenetics if patient < 55 years old
 No survival advantage if low-risk cytogenetics
 Unclear in intermediate risk cytogenetics

 No advantage to autologous HSCT in CR1 over
conventional chemotherapy

 Allogeneic HSCT in CR2 is recommended
 Insufficient data to recommend a MUD over autologous HSCT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Myelodysplastic Syndrome (MDS) Timing of Transplant Consultation -3

OS early 40%

A

 Intermediate-1 (INT-1), intermediate-2 (INT-2)
or high IPSS score which includes either:
 > 5% marrow blasts
 Other than good risk cytogenetics (good risk includes 5q- or normal)
 > 1 lineage cytopenia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

MDS Key Recommendations -2

A

 Autologous is only recommended as part of a clinical trial

 Allogeneic HSCT early in the disease course is recommended for
 IPSS score of intermediate-2 or high risk
 Have a suitable donor
 Meet HSCT criteria
 IPSS score of Intermediate -1 who have poor prognostic features not included in IPSS (older age, refractory cytopenias)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Chronic Myeloid Leukemia (CML)
Timing of Transplant Consultation -5

OS CP 70%
OS AP 40-45%

A

 No hematologic or minor cytogenetic response 3 months post-imatinib initiation

 No complete cytogenetic response 6-12 months post imatinib initiation

 2nd Relapse

 Accelerated phase

 Blast crisis (myeloid or lymphoid)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

CML Key Recommendations -1

&&&may be more- panotumib update

A

 CML – Accelerated phase and blast crisis
 Allogeneic HSCT as soon as CML – CP can be
achieved with TKI and/or chemotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

CLL Key Recommendations - 3

OS 40% (does not really flatten out)

def high risk CLL -3

A

 Autologous HSCT
 2 prospective RCT show improved EFS, but no
impact on overall survival (NOT DONE)

 Allogeneic HSCT
 Myeloablative conditioning generally not recommended because of high TRM (NOT DONE)
 RIC considered for patients with high-risk CLL
1. Deletion 17p or 11q;
2. refractory to chemoimmunotherapy
3. who develop recurrence within 12 months after purine analog treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Non Hodgkin’s Lymphoma (NHL) Timing of Transplant Consultation - Diffuse large B-cell lymphoma -3
50% OS vs 30% with chemo insensitive dz (same as chemo)

A

 At 1st or subsequent relapse

 CR1 for patients with high or high-intermediate IPI risk

 No CR with initial treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Non Hodgkin’s Lymphoma (NHL) Timing of Transplant Consultation - Follicular -4

A

 Poor response to initial treatment

 Initial remission duration < 12 months

 Second relapse

 Transformation to diffuse large B cell lymphoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Non Hodgkin’s Lymphoma (NHL) Timing of Transplant Consultation - Mantle Cell Lymphoma -3

A

 Following initial therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
NHL Key Recommendations - DLBCL -2
 Autologous HSCT recommended in 1st chemosensitive relapse as it improves survival  Not recommended in 1st CR for any IPI risk or in partial remission after 3 cycles of chemotherapy
26
NHL Key Recommendations - FL -4
 Autologous HSCT recommended for transformed follicular lymphoma  Autologous HSCT NOT recommended in CR1  No overall survival benefit  No comparative data with rituximab-containing regimens  Higher incidence of therapy related AML/MDS
27
NHL Key Recommendations - mantle cell -1
Many experts recommend autologous HSCT in CR1 PROBABLY NOT TESTABLE
28
Hodgkin’s Disease Timing of Transplant Consultation -2 OS CR 70% OS not CR sens 60% OS not CR insens 40%
 No initial CR  1st or subsequent relapse
29
Hodgkin’s Disease Key Recommendations -3
 Autologous HSCT is recommended in 1st chemosensitive relapse -outcomes improved over conventional therapy in randomized trials  Autologous HSCT is recommended in patients with refractory disease- outcomes improved over conventional therapy  RIC Allogeneic considered in eligible patients with no other options (including clinical trials)
30
Multiple Myeloma Timing of Transplant Consultation -2 no cure, OS 45% at 6yr
 After initiation of therapy  At first progression
31
Multiple Myeloma Key Recommendations -8
 Single Autologous HSCT  RCT demonstrated improved EFS over conventional chemotherapy  3 of 7 RCT demonstrated a benefit in OS  Considered standard of care  Tandem Autologous HSCT  3 RCT demonstrated an improvement in EFS  Only 1 RCT demonstrated a benefit in OS  Tandem autologous HSCT considered in patients with less than a very good partial response to 1st HSCT  Allogeneic  Comparative studies demonstrate similar or worse survival in myeloablative allogeneic HSCT compared with autologous HSCT -high TRM with myeloablative conditioning  1 of 3 RCT demonstrated improvement in survival with autologous HSCT followed by a RIC allogeneic HSCT compared with a tandem autologous HSCT
32
Severe Aplastic Anemia (SAA) Key Recommendations -2 OS MRD 70-87% OS MUD 50-67%
 Matched related donor BMT  Recommended for initial therapy for newly diagnosed patients if they have severe or very SAA and are <50 years old (or 50–60 years old with good performance status), and has failed at least one course of antithymocyte globulin and cyclosporine
33
Solid Tumor Key Recommendations - Germ Cell Tumors
Autologous HSCT recommended for relapsed | disease- may be curative
34
Solid Tumor Key Recommendations - High-Risk Neuroblastoma
Autologous HSCT recommended as part of first line | therapy (current trial comparing single vs. tandem)
35
HSCT Pre-transplant Process - Patient Evaluation -10
 Appropriateness of HSCT • Disease and stage, age, PS, organ function • Chemosensitivity ```  Patient evaluation • History & Physical • CBC + chemistries • Virology • Blood & HLA typing • Cardiac/Pulmonary • CXR; Labs • CT scans; Disease evaluation • Urinalysis; Pregnancy ```
36
HSCT Pre-transplant Process - Donor Evaluation -8
* HLA typing * History & Physical * CBC + chemistries * PT/ APTT * Blood type * Virology * Cardiac studies * Pregnancy test
37
Stem Cell Collection -Bone marrow harvest -3
 Multiple aspirations of posterior iliac crest  Requires general anesthesia; Limited by health of donor; Serious adverse event rate < 0.3%  10-20 mL/kg recipient weight = TNC 2 - 4 x 108/kg
38
Stem Cell Collection -Peripheral blood stem cell harvest =3
 Requires “mobilization” of cells  No anesthesia; may require multiple apheresis  Minimal risks:  dec Ca2+, anemia, thrombocytopenia, hypotension, thrombosis
39
Stem Cell Collection -Umbilical cord blood
Collected before or after placental delivery
40
slide 19C
&&&
41
Stem Cell Mobilization - allo -1
Filgrastim alone
42
Stem Cell Mobilization - auto -4
 Colony stimulating factor alone (filgrastim or sargramostim or both)  Colony stimulating factor + chemotherapy  Colony stimulating factor + plerixafor  Colony stimulating factor + chemotherapy + plerixafor
43
Factors Negatively Affecting Stem Cell Mobilization -7
 Tumor infiltration of bone marrow  Fibrotic bone marrow  Pelvic or abdominal irradiation  Marrow hypocellularity  Prior exposure to stem cell toxin  Alkylating agents; nitrosoureas; fludarabine; lenalidomide  Number of prior regimens; duration of exposure, short interval since last chemotherapy  Age > 60 – 70 years  Baseline platelet count < 150 x 109/L
44
Plerixafor + filgrastim
more cells collected, fewer median apheresis sessions, less mobilization failures than filgrastim alone
45
slide 20C-21A
&&&
46
HSCT Conditioning Regimens -ALLO MALIGNANT -4
immunosuppress (anti-graft rejection) make space (ablate) eradicate dz (anti-tumor) avoid overlapping toxicities
47
HSCT Conditioning Regimens -ALLO NON-MALIGNANT -3
immunosuppress (anti-graft rejection) make space (ablate) avoid overlapping toxicities
48
HSCT Conditioning Regimens -AUTO -3
make space (ablate) eradicate dz (anti-tumor) avoid overlapping toxicities
49
22C
study slide!!! ADR
50
Dz Sensitivity to GVT Effects
CLL, low-grade NHL, CML, Mantle cell NHL (CAN USE NON-MYELOABLATIVE) > Intermediate- grade NHL, AML, MM, HD > High grade- NHL, ALL
51
HSCT Conditioning Regimen Intensity Defined - Myeloablative (MA) regimens
Irreversible cytopenia and stem cell support is mandatory
52
HSCT Conditioning Regimen Intensity Defined - Nonmyeloablative (NMA) regimens
 Minimal cytopenia; given with or without stem cell support  Rely on immunosuppression to allow engraftment  Tumor eradication depends on GVT effects  Low dose total body irradiation and immunosuppressive chemotherapy
53
HSCT Conditioning Regimen Intensity Defined -RIC regimens do not fit criteria for MA or NMA
Cytopenia of variable duration, should be given with stem cell support
54
“High-dose” TBI
800-1320 cGy
55
“Low-dose” TBI
200-400 cGy
56
myeloablative ex regimen
Cy/TBI, BEAM
57
RIC ex regimen
Flu/Bu/ATG (Bu is 1mg/kg q6h), Flu/melphalan
58
NON-myeloablative ex regimen
Flu/low dose TBI
59
Comparing RIC/NMA to | Myeloablative Conditioning
 Risk of NRM is lower with RIC/NMA  Fewer inpatient hospital days  Reduced need for transfusion  Shorter duration of neutropenia & dec bacterial infections  Risk of relapse is higher with RIC/NMA  Risk of PFS (? and OS) is similar (because need for GVT effect)  Risk of acute GVHD before day 100 may be lower, but patients develop late-onset acute GVHD  Incidence of chronic GVHD is similar
60
Causes of Death after Transplants performed in 2008-2009 - primary dz
MRD: 33 MUD: 47 auto: 73
61
Causes of Death after Transplants performed in 2008-2009 - GVHD
MRD: 14 MUD: 19 auto: 0
62
Causes of Death after Transplants performed in 2008-2009 - infection
MRD: 12 MUD: 16 auto: 8
63
HSCT Preparative Chemotherapy Non-Hematologic DLT -BUSULFAN
hepatotoxicity pulmonary tox GI
64
HSCT Preparative Chemotherapy Non-Hematologic DLT -CARBOPLATIN
nephrotox ototoxicity pulmonary tox
65
HSCT Preparative Chemotherapy Non-Hematologic DLT -CARMUSTINE
pulmonary tox hepatotoxicity
66
HSCT Preparative Chemotherapy Non-Hematologic DLT -CYCLOPHOS
cardiotox
67
HSCT Preparative Chemotherapy Non-Hematologic DLT -CYTARABINE
neurotox
68
HSCT Preparative Chemotherapy Non-Hematologic DLT -ETOPOSIDE
mucositis
69
HSCT Preparative Chemotherapy Non-Hematologic DLT -FLUDARABINE
neurotox
70
HSCT Preparative Chemotherapy Non-Hematologic DLT -IFOS
nephrotox neurotox bladder tox
71
HSCT Preparative Chemotherapy Non-Hematologic DLT -MELPHALAN
mucositis
72
HSCT Preparative Chemotherapy Non-Hematologic DLT -THIOTEPA
neurotox mucositis
73
HSCT Preparative Chemotherapy Non-Hematologic DLT -TBI
pulmonary tox hepatotoxicity GI

BCOP (32 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions